xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05969600</url>
    </required_header>
    <id_info>
      <org_study_id>leukemia</org_study_id>
      <nct_id>NCT05969600</nct_id>
    </id_info>
    <brief_title>The Relapses in Childhood Acute Lymphoplastic Leukemia Excluding L3</brief_title>
    <official_title>The Relapses in Childhood Acute Lymphoplastic Leukemia Excluding L3: Experience of Single Institute/ Baghdad</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Central Teaching Hospital of Peadiatrics, Baghdad</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Central Teaching Hospital of Peadiatrics, Baghdad</source>
    <oversight_info>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        Background: acute lymphoblastic leukemia is the most common childhood cancer and relapse is&#xD;
        the main reason for treatment failure in childhood acute lymphoblastic leukemia.&#xD;
  &#xD;
        The aim of this study: is to assess the relapse of childhood acute lymphoblastic leukemia in&#xD;
        pediatric patients treated in the Child's Central Teaching Hospital/ Baghdad.&#xD;
  &#xD;
        Methods: A retrospective study that reviewed 521 children with newly diagnosed ALL for&#xD;
        children below 15 years during the period from 1st of January 2013 to 1st of March 2020 in&#xD;
        the hemato-oncology ward in the Child's Central Teaching Hospital in Baghdad, with a total&#xD;
        duration of follow-up for two years post last starting treatment (till 1st of March 2022 ).&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Six hundred patients diagnosed with acute lymphoblastic leukemia, seventy-nine patients were&#xD;
        excluded from study, nine patients died very early before starting induction, seventy&#xD;
        patients referred or starting treatment in another centers.&#xD;
  &#xD;
        The medical history, laboratory data had been taken for patients including age, gender,&#xD;
        residence, date of diagnosis, date of treatment, outcome of induction period and time of&#xD;
        relapse, investigations at time of relapse, therapy and relapse outcome were carried out&#xD;
        through chart analysis.&#xD;
  &#xD;
        The initial diagnosis of ALL was done through bone marrow aspiration morphological&#xD;
        classification of blast cells was performed according to the FAB method while&#xD;
        immunophenotyping not done for all patients (not available in the period from 2013 to 2016(&#xD;
        227 cases not diagnosed by flowcytometry,294 cases diagnosed by flowcytometry), cytogenetic&#xD;
        study not available in our country. The initial diagnostic screen (complete blood count and&#xD;
        blood film, renal function test and serum electrolytes and serum uric acid, liver function&#xD;
        tests, hepatitis screen, chest x ray, echo-study, computerized tomography and MRI done for&#xD;
        indicated cases.&#xD;
  &#xD;
        Risk group of patients at time of intial diagnosis divided into standard risk group (age&#xD;
        between 1 years and 9.9 years and initial WBC count less than50000) and high risk group (age&#xD;
        less than 1 and more than 10 years and WBC count more than 50000 and T cell leukemia) .&#xD;
  &#xD;
        Patients regarded and treated as T cell leukemia either by flow cytometry or on clinical&#xD;
        bases (mediastinal widening) which associated with(older age,high WBC count, lymphadenopathy,&#xD;
        hepatosplenomegaly).&#xD;
  &#xD;
        The patients were treated initially with regimens modified from United Kingdom Acute&#xD;
        Lymphocytic Leukemia protocols (306 patients were treated by UKALL 2003 for precursor B cell&#xD;
        with modification on protocol by increasing the number of intra-thecal dose during period of&#xD;
        induction therapy and 22 patients were treated by NHL/BFM 95 protocols for T cell leukemia&#xD;
        and used from 1st January 2013 to 1st October 2017, and 193 patients were treated with&#xD;
        modified MRC ALL 2011,the modification done by increasing number of intr-thecal dose during&#xD;
        the induction period and decreasing high dose of methotrexate from 5 g/m2 to 2g/m2 , from 1st&#xD;
        of October to 1st of March 2020) .&#xD;
  &#xD;
        The treatment protocols for relapsed cases were modified from MRC-UKALL -R3 protocol , the&#xD;
        modification was clofarabin not available and patients were treated by intermediate R3&#xD;
        protocol to adapt local limitation of supportive measures and the shortage of&#xD;
        chemotherapeutic agents.&#xD;
  &#xD;
          -  Infantile leukemia was treated with same protocol and treated as high risk group.&#xD;
  &#xD;
          -  CNS positive at time of patients presentation treated according to their age and WBCs&#xD;
             count .&#xD;
  &#xD;
          -  Limitation of study : cytogenetic study and MRD are not available in country at time of&#xD;
             study .&#xD;
  &#xD;
          -  B.M.A was done at day eight and day fifteen after started induction and according to the&#xD;
             results shifted to another protocol.&#xD;
  &#xD;
        Definition of relapse:&#xD;
  &#xD;
        An isolated BM relapse was diagnosed with 25% lymphoblast in the BM and without evidence of&#xD;
        leukemia at extra medullary sites. Accordingly, isolated extramedullary relapses were those&#xD;
        with the clinically-overt extramedullary manifestation of leukemia and less than 5% marrow&#xD;
        infiltration. CNS relapse was diagnosed in the case of positive the unequivocal presence of&#xD;
        lymphoblasts per microliter CSF or clinical signs of CNS leukemia such as facial nerve palsy,&#xD;
        brain/eye involvement .&#xD;
  &#xD;
        Testicular relapse was diagnosed by clinical examination and ultrasound, the involvement of&#xD;
        any other extramedullary site was confirmed histologically.in this study one case presented&#xD;
        with late relapse of cervical lymph node and biopsy done that show T lymphoblastic lymphoma&#xD;
        with blast cell less than 1% in B.M. In children with proven leukemia at extramedullary&#xD;
        sites, a combined relapse was diagnosed with marrow involvement of lymphoblasts.&#xD;
  &#xD;
        Complete remission was defined as the absence of leukemic blasts in peripheral blood and CSF&#xD;
        and less than 5% blast on bone marrow aspirate smear, together with hematopoietic&#xD;
        regeneration and no evidence of extramedullary (localized) disease.&#xD;
  &#xD;
        Induction failure was defined as the failure to achieve remission after 1 month of therapy.&#xD;
  &#xD;
        Abandonment of treatment was defined as care termination by the parent/caregiver and/or if&#xD;
        more than 4 weeks was exceeded with a no-show/non-attendance for a scheduled treatment by the&#xD;
        patient .&#xD;
  &#xD;
        Overall survival defined as the time from date of diagnosis and or start treatment to the&#xD;
        date of death.&#xD;
  &#xD;
        Time of relapse&#xD;
  &#xD;
        Based on time factor, relapses were categorized as:&#xD;
  &#xD;
          -  Very early: within 18 months of diagnosis, while on chemotherapy&#xD;
  &#xD;
          -  Early: occurred after 18 months of diagnosis and within 6 months of treatment completion&#xD;
  &#xD;
          -  Late: relapse documented more than 6 months after completion of therapy.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Completed</overall_status>
    <start_date type="Actual">January 1, 2013</start_date>
    <completion_date type="Actual">March 1, 2022</completion_date>
    <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
    <study_type>Observational</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Cohort</observational_model>
      <time_perspective>Retrospective</time_perspective>
    </study_design_info>
    <primary_outcome>
      <measure>the relapse of childhood acute lymphoblastic leukemia in pediatric patients treated in the Child's Central Teaching Hospital/ Baghdad</measure>
      <time_frame>the period from 1st of January 2013 to 1st of March 2020</time_frame>
      <description>521 children reviewed with newly diagnosed ALL for children below 15 years</description>
    </primary_outcome>
    <number_of_groups>2</number_of_groups>
    <enrollment type="Actual">521</enrollment>
    <condition>Leukemia, Acute</condition>
    <arm_group>
      <arm_group_label>relapse group</arm_group_label>
    </arm_group>
    <arm_group>
      <arm_group_label>non-relapse group</arm_group_label>
    </arm_group>
    <eligibility>
      <study_pop>
        <textblock>
          A retrospective study that reviewed 521 children with newly diagnosed ALL for children&#xD;
          below 15 years during the period from 1st of January 2013 to 1st of March 2020 in the&#xD;
          hemato-oncology ward in the Child's Central Teaching Hospital in Baghdad, with a total&#xD;
          duration of follow-up for two years post last starting treatment (till 1st of March 2022 ).&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Non-Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  patients diagnosed with acute lymphoplastic leukemia&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  patients died before starting induction chemotherapy.&#xD;
  &#xD;
            -  patients referred to another oncological center.&#xD;
  &#xD;
            -  those who starting the treatment in another oncological center&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>2 Months</minimum_age>
      <maximum_age>15 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>June 8, 2023</study_first_submitted>
    <study_first_submitted_qc>July 23, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 1, 2023</study_first_posted>
    <last_update_submitted>July 23, 2023</last_update_submitted>
    <last_update_submitted_qc>July 23, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 1, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Central Teaching Hospital of Peadiatrics, Baghdad</investigator_affiliation>
      <investigator_full_name>Maha Kharbat Shadhar Al-Magsoosi</investigator_full_name>
      <investigator_title>doctor</investigator_title>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Leukemia</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>Undecided</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05969600
  org study id: leukemia
  nct id: NCT05969600
  lead sponsor: 
  is fda regulated drug: No
  is fda regulated device: No
  Background: acute lymphoblastic leukemia is the most common childhood cancer and relapse is
        the main reason for treatment failure in childhood acute lymphoblastic leukemia.
  
        The aim of this study: is to assess the relapse of childhood acute lymphoblastic leukemia in
        pediatric patients treated in the Child's Central Teaching Hospital/ Baghdad.
  
        Methods: A retrospective study that reviewed 521 children with newly diagnosed ALL for
        children below 15 years during the period from 1st of January 2013 to 1st of March 2020 in
        the hemato-oncology ward in the Child's Central Teaching Hospital in Baghdad, with a total
        duration of follow-up for two years post last starting treatment (till 1st of March 2022 ).
  Six hundred patients diagnosed with acute lymphoblastic leukemia, seventy-nine patients were
        excluded from study, nine patients died very early before starting induction, seventy
        patients referred or starting treatment in another centers.
  
        The medical history, laboratory data had been taken for patients including age, gender,
        residence, date of diagnosis, date of treatment, outcome of induction period and time of
        relapse, investigations at time of relapse, therapy and relapse outcome were carried out
        through chart analysis.
  
        The initial diagnosis of ALL was done through bone marrow aspiration morphological
        classification of blast cells was performed according to the FAB method while
        immunophenotyping not done for all patients (not available in the period from 2013 to 2016(
        227 cases not diagnosed by flowcytometry,294 cases diagnosed by flowcytometry), cytogenetic
        study not available in our country. The initial diagnostic screen (complete blood count and
        blood film, renal function test and serum electrolytes and serum uric acid, liver function
        tests, hepatitis screen, chest x ray, echo-study, computerized tomography and MRI done for
        indicated cases.
  
        Risk group of patients at time of intial diagnosis divided into standard risk group (age
        between 1 years and 9.9 years and initial WBC count less than50000) and high risk group (age
        less than 1 and more than 10 years and WBC count more than 50000 and T cell leukemia) .
  
        Patients regarded and treated as T cell leukemia either by flow cytometry or on clinical
        bases (mediastinal widening) which associated with(older age,high WBC count, lymphadenopathy,
        hepatosplenomegaly).
  
        The patients were treated initially with regimens modified from United Kingdom Acute
        Lymphocytic Leukemia protocols (306 patients were treated by UKALL 2003 for precursor B cell
        with modification on protocol by increasing the number of intra-thecal dose during period of
        induction therapy and 22 patients were treated by NHL/BFM 95 protocols for T cell leukemia
        and used from 1st January 2013 to 1st October 2017, and 193 patients were treated with
        modified MRC ALL 2011,the modification done by increasing number of intr-thecal dose during
        the induction period and decreasing high dose of methotrexate from 5 g/m2 to 2g/m2 , from 1st
        of October to 1st of March 2020) .
  
        The treatment protocols for relapsed cases were modified from MRC-UKALL -R3 protocol , the
        modification was clofarabin not available and patients were treated by intermediate R3
        protocol to adapt local limitation of supportive measures and the shortage of
        chemotherapeutic agents.
  
          -  Infantile leukemia was treated with same protocol and treated as high risk group.
  
          -  CNS positive at time of patients presentation treated according to their age and WBCs
             count .
  
          -  Limitation of study : cytogenetic study and MRD are not available in country at time of
             study .
  
          -  B.M.A was done at day eight and day fifteen after started induction and according to the
             results shifted to another protocol.
  
        Definition of relapse:
  
        An isolated BM relapse was diagnosed with 25% lymphoblast in the BM and without evidence of
        leukemia at extra medullary sites. Accordingly, isolated extramedullary relapses were those
        with the clinically-overt extramedullary manifestation of leukemia and less than 5% marrow
        infiltration. CNS relapse was diagnosed in the case of positive the unequivocal presence of
        lymphoblasts per microliter CSF or clinical signs of CNS leukemia such as facial nerve palsy,
        brain/eye involvement .
  
        Testicular relapse was diagnosed by clinical examination and ultrasound, the involvement of
        any other extramedullary site was confirmed histologically.in this study one case presented
        with late relapse of cervical lymph node and biopsy done that show T lymphoblastic lymphoma
        with blast cell less than 1% in B.M. In children with proven leukemia at extramedullary
        sites, a combined relapse was diagnosed with marrow involvement of lymphoblasts.
  
        Complete remission was defined as the absence of leukemic blasts in peripheral blood and CSF
        and less than 5% blast on bone marrow aspirate smear, together with hematopoietic
        regeneration and no evidence of extramedullary (localized) disease.
  
        Induction failure was defined as the failure to achieve remission after 1 month of therapy.
  
        Abandonment of treatment was defined as care termination by the parent/caregiver and/or if
        more than 4 weeks was exceeded with a no-show/non-attendance for a scheduled treatment by the
        patient .
  
        Overall survival defined as the time from date of diagnosis and or start treatment to the
        date of death.
  
        Time of relapse
  
        Based on time factor, relapses were categorized as:
  
          -  Very early: within 18 months of diagnosis, while on chemotherapy
  
          -  Early: occurred after 18 months of diagnosis and within 6 months of treatment completion
  
          -  Late: relapse documented more than 6 months after completion of therapy.
  observational model: Cohort
  time perspective: Retrospective
  measure: the relapse of childhood acute lymphoblastic leukemia in pediatric patients treated in the Child's Central Teaching Hospital/ Baghdad
  time frame: the period from 1st of January 2013 to 1st of March 2020
  description: 521 children reviewed with newly diagnosed ALL for children below 15 years
  arm group label: relapse group
  arm group label: non-relapse group
  study pop: 
  sampling method: Non-Probability Sample
  criteria: 
  gender: All
  minimum age: 2 Months
  maximum age: 15 Years
  healthy volunteers: No
  responsible party type: Principal Investigator
  investigator affiliation: Central Teaching Hospital of Peadiatrics, Baghdad
  investigator full name: Maha Kharbat Shadhar Al-Magsoosi
  investigator title: doctor
  mesh term: Leukemia
  sharing ipd: Undecided